Formation of DNA adducts and induction of lacI mutations in big blue rat-2 cells treated with temozolomide: Implications for the treatment of low-grade adult and pediatric brain tumors

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 6, 2003, Pages 545-551

  Bodell, William J ^a,b   Gaikwad, Nilesh W ^a   Miller, Douglas ^a   Berger, Mitchel S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MUTAGENIC AGENT; TEMOZOLOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; BRAIN TUMOR; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA ADDUCT; GENE MUTATION; LEUKEMOGENESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SEQUENCE ANALYSIS;

ALKYLATION; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE MODELS, ANIMAL; DNA ADDUCTS; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GENE FREQUENCY; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POINT MUTATION; RATS; SEVERITY OF ILLNESS INDEX; STATISTICS; TIME FACTORS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0038119669     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Stevens, M. F., and Newlands, E. S. From triazines and triazenes to temozolomoide. Eur. J. Cancer, 29A:1045-1047, 1993.
2. Newlands, E., S., Stevens, M. F., Wedge, S. R., Wheelhouse, R. T., and Brock, C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev., 23: 35-61, 1977.
3. Newlands, E. S., O'Reilly, S. M., Glaser, M. G., Bower, M., Evans, H., Brock, C., Brampton, M. H., Colquhoun, I., Lewis, P., Rice-Edwards, J. M., Illingworth, R. D., and Richards, P. G. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur. J. Cancer, 32A: 2236-2244, 1996.
4. Bower, M., Newlands, E. S., Bleehen, N. M., Brada, M., Begent, R. J., Calvert, H., Colquhoun, I., Lewis, P., and Brampton, M. H. Mutlicentre CRC phase II study of temozolomide in recurrent or progressive high grade glioma. Cancer Chemother. Pharmacol., 40: 484-488, 1977.
5. Yung, W. K., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R. G., Vick, N. A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., and Levin, V. A., A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer, 83: 588-593, 2000.
6. Yung, W. K. A., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R., Olson, J., Chang, S. M., O'Neill, A. M., Friedman, A. H., Bruner, J., Yue, N., Dugan, M., Zaknoen, S., and Levin, V. A. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or ana-plastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol., 17: 2762-2771, 1999.
7. Chinot, O. L., Honore, S., Dufour, H., Barrie, M., Figarella-Branger, D., Muracciole, X., Braguer, D., Martin, P. M., and Grisoli, F., Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. Oncol., 19: 2449-2455, 2001.
8. van Den Bent, M. J., Keime-Guibert, F., Brandes, A. A., Taphoorn, M. J., Kros, J. M., Eskens, F. A., and Carpentier, A. F. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology, 57: 340-342, 2001.
9. Schold, S. C., Jr., Kuhn, J. G., Chang, S. M., Bosik, M. E., Robins, H. I., Mehta, M. P., Spence, A. M., Fulton, D., Fink, K. L., and Prados, M. D. A phase I trial of 1, 3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. J. Neuro-Oncol., 2: 34-39, 2000.
10. Nicholson, H. S., Krailo, M., Ames, M. M., Seibel, N. L., Reid, J. M., Liu-Mares, W., Vezina, L. G., Ettinger, A. G., and Reaman, G. H. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. J. Clin. Oncol., 16: 3037-3043, 1998.
11. Groves, M. D., Puduvalli, V. K., Hess, K. R., Jaeckle, K. A., Peterson, P., Yung, W. K., and Levin, V. A. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol., 20:1383-1388, 2002.
12. Bennett, R. A., and Pegg, A. E. Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res., 41: 2786-2790, 1981.
13. Wiestler, O. D., Kleihues, P., Rice, J. M., and Ivankovic, S. DNA methylation in maternal, fetal and neonatal rat tissues following perinatal administration of procarbazine. J. Cancer Res. Clin. Oncol., 108: 56-59, 1984.
14. Meer, L., Janzer, R. C., Kleihues, P., and Kolara, G. F. In vivo metabolism and reaction with DNA of the cytostatic agent 5-(3, 3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). Biochem. Pharmacol., 35: 3243-3247, 1986.
15. 6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationship with dose and repair. Cancer Res., 50: 2759-2764, 1990.
16. van Delft, J. H. M., van den Ende, A. M. C., Keizer, H. J., Ouwerkerk, J., and Baan, R. A. Determination of N7-methlyguanine in DNA of white blood cells from patients treated with dacarbazine. Carcinogenesis (Lond.), 13:1257-1259, 1992.
17. 32P-postlabeling of 7-methylguanine levels in white blood cell DNA of healthy individuals and cancer patients treated with dacarbazine and procarbazine. Human data and method development for 7-alkylguanines. Carcinogenesis, 12:1423-1431, 1991.
18. Fong, L. Y. Y., Bevill, R. F., Thurmon, J. C., and Magee, P. N. DNA adduct dosimetery and DNA repair in rats and pigs given repeated doses of procarbazine under conditions of carcinogenicity and human cancer chemotherapy respectively. Carcinogenesis (Lond.), 13: 2153-2159, 1992.
19. 6-methylguanine in humans and rodents treated with dacarbazine. Carcinogenesis (Lond.), 17: 725-732, 1996.
20. 6-alkylguanine DNA lesions trigger apoptosis. Carcinogenesis (Lond.), 19: 369-372, 1998.
21. Lange, H., and Dietel, M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J. Cancer Res. Clin. Oncol., 125:156-165, 1999.
22. Myhr, B. C. Validation studies with Muta Mouse: a transgenic model for detecting mutations in vivo. Environ. Mol. Mutagen., 18: 308-315, 1991.
23. Schmezer, P., Eckeryt, C., and Liegibel, U. M. Tissue-specific induction of mutations by streptozotocin in vivo. Mutat. Res., 307: 495-499, 1994.
24. 6-methylguanine. Carcinogenesis, 18: 2191-2196, 1997.
25. Suzuki, T., Uno, Y., Idehara, K., Baba, T., Maniwa, J., Ohkouchi, A., Wang, X., Hayashi, M., Sofuni, T., Tsuruoka, M., Miyajima, H., and Kondo, K. Procarbazine genotoxicity in the Muta Mouse: strong clastogenicity and organ-specific induction of lacZ mutations. Mutat. Res., 444: 269-281, 1999.
26. Weisburger, E. K. Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents. Cancer (Phila.), 40:1935-1949, 1977.
27. IARC. Procarbazine Hydrochloride. IARC Sci. Publ., 26: 311-339, 1981.
28. Hard, C. G. Identification of a high frequency model for renal carcinoma by the induction of renal tumors in the mouse with a single dose of streptozotocin. Cancer Res., 45: 703-706, 1985.
29. Pedersen-Bjergaard, J. Radiotherapy and chemotherapy induced myelodysplasia and acute myeloid leukemia. A review. Leuk. Res., 16: 61-65, 1992.
30. Ng, A., Taylor, G. M., and Eden, O. B. Treatment related leukemia-a clinical and scientific challenge. Cancer Treat. Rev., 26: 377-391, 2000.
31. Cohen, R. J., Wiernik, P. H., and Walker, M. D. Acute nonlymphocytic leukemia associated with nitrosourea chemotherapy: report of two cases. Cancer Treat. Rep., 60:1257-1261, 1976.
32. Genot, J-Y., Krulik, M., Poisson, M., Van Efferterre, R., Renoux, M., Audebert, A. A., Canuel, C., Smadja, N., and Debray, J. Two cases of acute leukemia following treatment of malignant glioma. Cancer (Phila.), 52: 222-226, 1983.
33. Perry, J. R., Brown, M. T., and Gockerman, J. P. Acute leukemia following treatment of malignant gliomas. J. Neuro-Oncol., 40: 39-46, 1998.
34. Chandler, K. L., Prados, M. D., Malec, M., and Wilson, C. B. Long-term survival in patients with glioblastoma multiforme. Neurosurgery, 32: 716-720, 1993.
35. Shaw, E. G., Scheithauer, B. W., and Dinapoli, R. P. Low-grade hemispheric astrocytomas. In: P. M Black and J. S. Loeffler (eds.), Cancer of The Nervous System, pp. 441-461.: Blackwell Science. 1997. Cambridge, MA.
36. Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., Ramsay, D. A., and Louis D. N. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. (Bethesda), 90:1473-1489, 1998.
37. Packer, R. J., Sutton, L. N., Elterman, R., Lange, B., Goldwein, J., Nicholson, H. S., Mulne, L., Boyett, J., D'Angio, G., Wechsler-Jentzsch, K., Reaman, G., Cohen, B. H., Bruce, D. A., Rorke, L. B., Molloy, P., Ryan, J., LaFond, D., Evans, A. E., and Schut, L. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU and vincristine chemotherapy. J. Neurosurg., 81: 690-698, 1994.
38. Le Beau, M. M., Albain, K. S., Larson, R. A., Vardiman, J. W., Davis, E. M., Blough, R. R., Golomb, H. M., and Rowley J. D. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no 5 and 7. J. Clin. Oncol., 4: 325-345, 1986.
39. Pedersen-Bjergaared, J., Janssen, J. W. G., Lyons, J., Philip, P., and Bartram, C. R. Point mutation of the ras protooncogenes and chromosome aberrations in acute nonlymphocytic leukemia and preleukemia related to therapy with alkylating agents. Cancer Res., 48:1812-1817, 1988.
40. Andersen, M. K., Christiansen, D. H., Kirchhoff, M., and Pedersen-Bjergaard, J. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer. 31: 33-41, 2001.
41. Christiansen, D. H., Andersen, M. K., and Pedersen-Bjergaard, J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype and a poor prognosis. J. Clin. Oncol., 19:1405-1413, 2001.
42. Hussain, S. P., and Harris, C. C. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat. Res., 428: 23-32, 1999.
43. Felix, C. A., Hosler, M. R., Provisor, D., Salhany, K., Sexsmith, E. A., and Slater, D. J., Cheung, N. K., Winick, N. J., Strauss, E. A., Heyn, R., Lange, B. J., and Malkin, D. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood. 87: 4376-4381, 1996.
44. Felix, C. A., Walker, A. H., Lange, B. J., Williams, T. M., Winick, N. J., and Cheung, N. K. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. USA, 95:13176-13181, 1998.
45. Larson, R. A., Wang, Y., Banerjee, M., Wiemels, J., Hartford, C., Le Beau, M. M., and Smith, M. T. Prevalence of the inactivating 609 C → T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO I) gene in patients with primary and therapy-related myeloid leukemia. Blood. 94: 803-807, 1999.
46. Allan, J. M., Wild, C. P., Rollinsin, S., Willert, E. V., Moorman, A. V., Dovey, G. J., Roddam, P. L., Roman, E., Cartwright, R. A., and Morgan, G. J. Poylmorphisms in glutathione S-transferase P1 is associated with susceptibility to chemotherapy induced leukemia. Proc. Natl. Acad. Sci. USA, 98:11592-11597, 2001.
47. Schering Plough. Temodar Product Information sheet, 1999.
48. Wyborski, D. L., Malkhoysan, S., Moores, J., Perucho, M., and Short, J. M. Development of a rat cell line containing stably integrated copies of a lambda/lacI shuttle vector. Mutat. Res., 334:161-165, 1995.
49. Zimmer, D. M., Zhang, P. R., Harbach, P. R., Mayo, J. K., and Aaron, C. S. Spontaneous and ethylnitrosourea-induced mutation fixation and molecular spectra at the lacI transgene in the Big Blue Rat-2 embryo cell line. Eniron. Mol. Mutagen., 28: 325-333, 1996.
50. Sprung, C. N., Wang, Y., Miller, D. L., Gianniai, D. D., Dhananjaya, N., and Bodell, W. J. Induction of lacI mutations in Big Blue Rat-2 cells treated with 1-(2-hydroxyethyl)-1-nitrosourea: a model system for the analysis of mutagenic potential of the hydroxyethyl adducts produced by 1, 3-bis (2-chloroethyl)-1-nitrosourea. Mutat. Res., 484: 77-86, 2001.
51. Bodell, W. J., Rupniak, H. T. R., Rasmussen, J., Morgan, W. F., and Rosenblum, M. L. Reduced level of DNA crosslinks and sister chromatid exchanges in 1, 3 bis (2-chloroethyl)-1-nitrosourea-resistant rat brain tumor cells. Cancer Res., 44: 3763-3767, 1984.
52. Ye, Q., and Bodell, W. J. Detection of N7-(2-hydroxyethyl) guanine adducts in DNA and 9L cells treated with 1-(2-chloroethyl)-1-nitrosourea. J. Chromatogr. B, 694: 65-70, 1977.
53. 14C-Temozolomide after p.o. administration to patients with advanced cancer. Clin. Cancer Res., 5: 309-317, 1999.
54. Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., and Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother. Rep., 50: 219-244, 1966.
55. 6-alkylguanine-DNA-alkyltransferase. Cancer Res., 60: 5464-5469, 2000.
56. 6-alkylation of deoxyguanosine to mutagenicity of nitrosoamines and nitrosoamides. Nature (Lond.), 233: 206-208, 1969.
57. Singer, B., and Essigmann, J. Site-specific mutagenesis: retrospective and prospective. Carcinogenesis (Lond.), 12: 949-955, 1991.
58. Perera, F. P., Motzer, R. J., Tang, D., Reed, E., Parker, R., Warburton, D., O'Neill, P., Albertini, R., Bigbee, W. L., Jensen, R. H., Santella, R., Tsai, W-Y., Simon-Cereijido, G., Randall, C., and Bosl, G. Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy. Cancer Res., 52: 3558-3565, 1992.
59. Philip, P. A., Souliotis, V. L., Harris, A. L., Salisbury, A., Tates, A. D., Mitchell, K., van Delft, J. H., Ganesan, T. S., and Kyrtopoulos, S. A. Methyl DNA adducts. DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. Clin. Cancer Res., 2: 303-310, 1996.
60. Kubota, M., Lin, Y. W., Hamahata, K., Sawada, M., Koishi, S., Hirota, H., and Wakazono, Y. Cancer chemotherapy and somatic cell mutation. Mutat. Res., 470: 93-102, 2000.
61. + hematopoietic stem cells. Mutat. Res., 431:183-198, 1999.